Authors
Christian M Farag, Ann Mercurio, Rejowana Rouf, Hannah Fried, Michelle Rudshteyn Korostin, Tianxiang Sheng, Douglas Tremblay, Risa Fuller, Hannah Levavi
Published in
Leukemia & lymphoma. Pages 1-12. Sep 06, 2026. Epub Sep 06, 2026.
Abstract
Invasive fungal infections (IFIs) cause substantial morbidity and mortality, yet optimal antifungal prophylaxis in adult acute lymphoblastic leukemia (ALL) remains uncertain given unclear incidence and drug interaction constraints. We performed a PRISMA 2020-compliant systematic review and meta-analysis (PROSPERO CRD420251048884) of PubMed, Embase, and Cochrane CENTRAL from inception through September 2025, including adults with ALL receiving antineoplastic therapy, excluding HSCT and pediatric cohorts. Primary outcome was IFI incidence per European Organization for Research and Treatment of Cancer and the Mycoses Study Group (EORTC/MSG) criteria; invasive aspergillosis (IA) was secondary. Of 1,789 records, 36 studies met eligibility; 23 contributed to meta-analyses. Pooled incidence of proven/probable IFI was 9% (95% CI 7-11%; N = 3,316), proven/probable/possible IFI 16% (12-21%; N = 806), and IA 5% (4-8%; N = 3,190). IFIs remain clinically significant in adult ALL, supporting risk-adapted prophylaxis during higher-risk treatment phases. Heterogeneity reflected differences in prophylaxis, treatment, and limited comparative data on strategies across studies.
PMID:
42702054
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0